DK2379497T3 - Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre - Google Patents

Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre

Info

Publication number
DK2379497T3
DK2379497T3 DK09793413.7T DK09793413T DK2379497T3 DK 2379497 T3 DK2379497 T3 DK 2379497T3 DK 09793413 T DK09793413 T DK 09793413T DK 2379497 T3 DK2379497 T3 DK 2379497T3
Authority
DK
Denmark
Prior art keywords
ethyl
benzyloxyimino
azetidine
trifluoromethyl
cyclohexyl
Prior art date
Application number
DK09793413.7T
Other languages
English (en)
Inventor
Lech Ciszewski
La Cruz Marilyn De
Piotr H Karpinski
Michael Mutz
Christian Riegert
Caspar Vogel
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2379497(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2379497T3 publication Critical patent/DK2379497T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09793413.7T 2008-12-18 2009-12-16 Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre DK2379497T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18
PCT/US2009/068143 WO2010080409A1 (en) 2008-12-18 2009-12-16 Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid

Publications (1)

Publication Number Publication Date
DK2379497T3 true DK2379497T3 (da) 2013-11-25

Family

ID=42236293

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09793413.7T DK2379497T3 (da) 2008-12-18 2009-12-16 Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
DK13177190.9T DK2676953T3 (da) 2008-12-18 2009-12-16 Hemifumaratsalt af 1-[4-[1-(4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-acetidin-3-carboxylsyre til anvendelse ved behandling af lymfocytmedierede sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13177190.9T DK2676953T3 (da) 2008-12-18 2009-12-16 Hemifumaratsalt af 1-[4-[1-(4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-acetidin-3-carboxylsyre til anvendelse ved behandling af lymfocytmedierede sygdomme

Country Status (36)

Country Link
US (6) US20120115840A1 (da)
EP (2) EP2379497B1 (da)
JP (1) JP5627597B2 (da)
KR (5) KR20110096584A (da)
CN (2) CN102256943A (da)
AR (3) AR074694A1 (da)
AU (1) AU2009335924B2 (da)
BR (1) BRPI0923176B8 (da)
CA (2) CA2747437C (da)
CL (1) CL2011001490A1 (da)
CO (1) CO6390104A2 (da)
CY (2) CY1114662T1 (da)
DK (2) DK2379497T3 (da)
EC (1) ECSP11011210A (da)
ES (2) ES2436197T3 (da)
HK (1) HK1159631A1 (da)
HR (2) HRP20131106T1 (da)
HU (1) HUE034819T2 (da)
IL (3) IL253845B (da)
JO (1) JO2894B1 (da)
LT (1) LT2676953T (da)
MA (1) MA32961B1 (da)
MX (1) MX2011006609A (da)
MY (1) MY152669A (da)
NZ (1) NZ593061A (da)
PE (2) PE20120336A1 (da)
PL (2) PL2676953T3 (da)
PT (2) PT2676953T (da)
RS (2) RS56110B1 (da)
RU (1) RU2518114C3 (da)
SG (1) SG171785A1 (da)
SI (2) SI2676953T1 (da)
TW (2) TWI591055B (da)
UY (1) UY32330A (da)
WO (1) WO2010080409A1 (da)
ZA (1) ZA201103709B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093161A1 (en) 2011-01-07 2012-07-12 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
IL305337A (en) * 2014-04-10 2023-10-01 Novartis Ag A therapeutic regimen containing an immediate release dose of an S1P modulator
PT3129006T (pt) 2014-04-10 2021-04-09 Novartis Ag Formulação imunossupressora
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7271517B2 (ja) * 2017-09-27 2023-05-11 ノバルティス アーゲー シポニモドを含む非経口製剤
JP2020535175A (ja) * 2017-09-27 2020-12-03 ドクター レディズ ラボラトリーズ リミテッド シポニモド、その塩およびその固体状態フォームの調製のためのプロセス
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
WO2019144094A1 (en) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (en) 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
EP4139282A2 (en) * 2020-05-29 2023-03-01 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof
WO2022064007A1 (en) 2020-09-25 2022-03-31 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 一种羧酸类化合物半富马酸盐的晶型及其制备方法
WO2022199865A1 (en) 2021-03-26 2022-09-29 Olon S.P.A. Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
ES2073868T3 (es) * 1991-06-04 1995-08-16 Fujisawa Pharmaceutical Co Una composicion profilactica/terapeutica para la pleuroneumonia del cerdo.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (da) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
WO1994028967A1 (fr) * 1993-06-08 1994-12-22 Hisamitsu Pharmaceutical Co., Inc. Systeme d'iontophorese
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69725585T2 (de) * 1996-04-04 2004-07-01 Sankyo Co., Ltd. Phenylalkylcarbonsäure-derivate
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
EP1309556B1 (en) * 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (en) 2003-06-13 2004-12-23 Stephen Dichiera Adjustable bed support and bed
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
BRPI0518674A2 (pt) * 2004-11-29 2008-12-02 Novartis Ag regime de dosagem de um agonista de receptor s1p
KR20080031936A (ko) * 2005-08-04 2008-04-11 노파르티스 아게 빌다글립틴의 염
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP2010508370A (ja) * 2006-11-07 2010-03-18 ノバルティス アーゲー ヘミフマル酸アリスキレンの結晶形

Also Published As

Publication number Publication date
NZ593061A (en) 2013-08-30
KR20180006492A (ko) 2018-01-17
UY32330A (es) 2010-07-30
EP2676953A1 (en) 2013-12-25
JP2012512881A (ja) 2012-06-07
US20220402870A1 (en) 2022-12-22
CY1114662T1 (el) 2016-10-05
BRPI0923176A2 (pt) 2016-02-16
SI2379497T1 (sl) 2013-12-31
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
HUE034819T2 (en) 2018-02-28
BRPI0923176A8 (pt) 2017-09-12
CO6390104A2 (es) 2012-02-29
KR20160129915A (ko) 2016-11-09
HK1159631A1 (da) 2012-08-03
DK2676953T3 (da) 2017-07-03
IL213071A0 (en) 2011-07-31
PL2379497T3 (pl) 2014-01-31
BRPI0923176B8 (pt) 2021-05-25
CL2011001490A1 (es) 2012-01-13
TW201509909A (zh) 2015-03-16
US20180118678A1 (en) 2018-05-03
HRP20170916T1 (hr) 2017-09-22
PT2379497E (pt) 2013-11-29
TWI591055B (zh) 2017-07-11
EP2379497B1 (en) 2013-08-21
EP2676953B1 (en) 2017-03-22
ECSP11011210A (es) 2011-08-31
KR101885052B1 (ko) 2018-08-02
KR20160064245A (ko) 2016-06-07
US20140005162A1 (en) 2014-01-02
BRPI0923176B1 (pt) 2020-12-01
AU2009335924B2 (en) 2012-11-08
AU2009335924A1 (en) 2011-06-30
LT2676953T (lt) 2017-06-26
AR074694A1 (es) 2011-02-02
SG171785A1 (en) 2011-07-28
US20120115840A1 (en) 2012-05-10
JP5627597B2 (ja) 2014-11-19
US20210323915A1 (en) 2021-10-21
MX2011006609A (es) 2011-06-30
AR121635A2 (es) 2022-06-22
HRP20131106T1 (hr) 2013-12-20
AR112227A2 (es) 2019-10-02
CA2747437A1 (en) 2010-07-15
RS53041B (en) 2014-04-30
MY152669A (en) 2014-10-31
JO2894B1 (en) 2015-09-15
IL253845B (en) 2022-08-01
RU2518114C3 (ru) 2021-11-24
EP2379497A1 (en) 2011-10-26
ES2631203T3 (es) 2017-08-29
WO2010080409A1 (en) 2010-07-15
ES2436197T3 (es) 2013-12-27
MA32961B1 (fr) 2012-01-02
IL253845A0 (en) 2017-09-28
TW201035048A (en) 2010-10-01
IL294514A (en) 2022-09-01
RU2518114C2 (ru) 2014-06-10
US20230357142A9 (en) 2023-11-09
CY1119037T1 (el) 2018-01-10
US20150175536A1 (en) 2015-06-25
CN104803902A (zh) 2015-07-29
PE20142374A1 (es) 2015-01-30
PE20120336A1 (es) 2012-04-30
PT2676953T (pt) 2017-06-29
CA2951479A1 (en) 2010-07-15
CA2747437C (en) 2018-08-21
RS56110B1 (sr) 2017-10-31
SI2676953T1 (sl) 2017-07-31
KR20170062554A (ko) 2017-06-07
RU2011129222A (ru) 2013-01-27
ZA201103709B (en) 2012-01-25
CN102256943A (zh) 2011-11-23
KR20110096584A (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
DK2379497T3 (da) Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
SMT201500227B (it) Metodo di decodifica di immagini
DK2246336T3 (da) Fibroseinhibitor
BRPI0913368A2 (pt) compostos de ácido carboxílico
HK1145175A1 (en) Compounds having crth2 antagonist activity
IL209980A0 (en) Sulfonamide compounds or salts thereof
ZA201006641B (en) Mtor inhibitor salt forms
DK2202225T3 (da) Ny fremgangsmåde til syntese af ivabradin og additionssalte heraf med en farmaceutisk acceptabel syre
HK1226051A1 (zh) 14-羥基-二十二烯酸化合物
BRPI0918564A2 (pt) inibidores
BRPI0909159A2 (pt) inibidores baseados em hidroxamato de desacetilases b
BRPI0922685A2 (pt) método de purificação do ácido clorídrico
FR2936378B1 (fr) Detection directionnelle d'un defaut a la terre a faible echantillonnage
BRPI0922838A2 (pt) método de purificação do ácido clorídrico
DK2364972T3 (da) Ny fremgangsmåde til syntetisering af ivabradin og dets additionssalte
EP2383275A4 (en) PROCESS FOR SYNTHESIZING O-DIPHENYLPHOSPHINOBENZOIC ACID
GB0801674D0 (en) Compounds having CRTH2 antagonist activity
IT1392028B1 (it) Terminale di ancoraggio per impalcature
ES1068961Y (es) Encofrado provisional
GB0801132D0 (en) Compounds having CRTH2 antagonist activity
GB0800874D0 (en) Compounds having CRTH2 antagonist activity
GB0801131D0 (en) Compounds having CRTH2 antagonist activity
GB0801671D0 (en) Compounds having crth2 antagonist activity
GB0801672D0 (en) Compounds having crth2 antagonist activity